• Recce Pharmaceuticals enters non-binding term sheet with Middle Eastern pharmaceutical company
• Potential 10-year exclusive licensing arrangement
• Counterparty is a leading publicly listed company with a multi-billion-dollar market capitalization

Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q) has announced the signing of a non-binding term sheet with a leading Middle Eastern pharmaceutical company for a proposed 10-year exclusive licensing arrangement. The company confirmed that the identity of the counterparty is not price-sensitive and that the initial announcement contained all relevant material information. The counterparty is a major publicly listed company with a multi-billion-dollar market capitalization and a distribution network spanning over 30 international markets. Recce reviewed the counterparty's financial reports as part of its due diligence, confirming their capacity to fulfill payment obligations.

The potential licensing agreement could significantly enhance Recce Pharmaceuticals' market presence and revenue streams.